Multiple Sclerosis (MS) Drug Market

FierceBiotech  May 21  Comment 
Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models...
Wall Street Journal  May 1  Comment 
Drugs for diseases such as cancer and multiple sclerosis account for more than a quarter of spending on prescriptions for America’s elderly and disabled, data show.
MedPage Today  Apr 27  Comment 
(MedPage Today) -- Water-soluble vitamin bests placebo in progressive multiple sclerosis.
MedPage Today  Apr 27  Comment 
(MedPage Today) -- Study suggests 75% of stable patients remain stable for 3 years after discontinuing drugs.
FiercePharma  Apr 27  Comment 
The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now...
Reuters  Apr 24  Comment 
Biogen Inc posted lower-then-expected quarterly profit and revenue as its key oral multiple sclerosis (MS) drug Tecfidera showed signs of slowing growth, sending the company's shares down 3 percent in premarket trading on Friday.
Benzinga  Apr 22  Comment 
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today presented data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). Safety data showed rHIgM22 was well-tolerated in each of...
MedPage Today  Apr 21  Comment 
(MedPage Today) -- Researcher creates new, visually appealing model of multiple sclerosis.
Benzinga  Apr 21  Comment 
Today Biogen (NASDAQ: BIIB) announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY® (peginterferon beta-1a) over three years in people with relapsing-remitting multiple sclerosis (RRMS). The...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki